BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/24/2026 6:11:16 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-04-08 03:35 |
|
Peer-Review Started |
|
2026-04-08 03:37 |
|
First Decision by Editorial Office Director |
|
2026-05-27 08:13 |
|
Return for Revision |
|
2026-05-27 09:11 |
|
Revised |
|
2026-06-10 08:39 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-06-25 02:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-06-25 02:58 |
|
Articles in Press |
|
2026-06-25 02:58 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-22 01:10 |
|
Publish the Manuscript Online |
|
2026-07-24 06:11 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Wei Guo, Xin-Xin Xu, Bing-Jie Deng, Guang-Fu Zhou, Qian Zhou, Xiao-Xin Gao, Cheng-Zhou Du, Zhi Qiao and Hong-Tao Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Military Health Care Project |
24BJZ15 |
| Gansu Provincial Science and Technology Project |
25JRRA1191 |
|
| Corresponding Author |
Hong-Tao Li, Associate Chief Physician, Associate Professor, Department of General Surgery, The 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, No. 333 South River Road, Lanzhou 730050, Gansu Province, China. lihongtao528@163.com |
| Key Words |
Locally advanced gastric cancer; Minimal residual disease; Circulating tumor DNA; Recurrence prediction; Treatment guidance; Neoadjuvant therapy |
| Core Tip |
Locally advanced gastric cancer remains difficult to cure because occult residual disease can drive recurrence after radical or multimodal therapy. Minimal residual disease (MRD) assessment using circulating tumor DNA (ctDNA) offers a non-invasive strategy for molecular surveillance, recurrence-risk stratification, and dynamic evaluation of treatment response. This minireview highlights current ctDNA-MRD technologies, introduces tumor-informed and tumor-agnostic approaches, and clarifies that ctDNA-MRD is promising but still investigational for treatment guidance. Standardized assays, validated thresholds, and prospective interventional trials are needed before routine precision management of locally advanced gastric cancer. |
| Publish Date |
2026-07-24 06:11 |
| Citation |
Guo XW, Xu XX, Deng BJ, Zhou GF, Zhou Q, Gao XX, Du CZ, Qiao Z, Li HT. Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer. World J Clin Oncol 2026; 17(7): 121993
|
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i7/121993.htm |
| DOI |
https://doi.org/10.5306/wjco.121993 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
